Current treatment of ITP attempts to either increase the level of TPO (TPO-RA) or decrease the immune response (corticotherapy, CD20-targeted monoclonal antibodies, immunoglobulins, immunosuppression, and splenectomy), or both [56,57] (Figure 2). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.